Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of andexanet alfa reversal followed by alteplase for acute ischemic stroke in patients taking NOACs
2020-004898-41Phase 2Active
- Sponsor
- Medical University of Gdańsk
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of andexanet alfa and tissue-plasminogen activator in ischemic stroke (2 arms), sponsored by Medical University of Gdańsk. Started Feb 2021; status: active.
02
Drugs
andexanet alfatissue-plasminogen activator
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2020-004898-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004898-41.